Andreas Bruns
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andreas Bruns has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Markus von Kienlin
Department of Biophysics, University of Würzburg, Würzburg, Germany
12 shared publications Basil Künnecke
Pharmaceutical Research and Early Development, Roche Innovation Center Basel , F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124 , 4070 Basel , Switzerland
9 shared publicationsJoseph G. Wettstein
Roche Pharmaceutical Research & Early Development, Neuroscience Discovery, Roche Innovation Center Basel, Switzerland
6 shared publicationsCéline Risterucci
Pharmaceutical Research and Early Development, Roche Innovation Center Basel , F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124 , 4070 Basel , Switzerland
5 shared publicationsThomas Mueggler
Pharmaceutical Research and Early Development, Roche Innovation Center Basel , F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124 , 4070 Basel , Switzerland
5 shared publications- Basil Künnecke
Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, Basel, Switzerland
4 shared publications
Latest Publications
- Open Access
- 21 November 2024
- Published by Elsevier in NeuroImage
- Vol. 304, 120934
Deep learning applied to the segmentation of rodent brain MRI data outperforms noisy ground truth on full-fledged brain atlases
- 21 November 2024
- Published by Elsevier in NeuroImage
- Vol. 304, 120934
Open AccessDeep learning applied to the segmentation of rodent brain MRI data outperforms noisy ground truth on full-fledged brain atlases
- 17 January 2020
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (4) , 1511-1525
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder
We recently reported the discovery of a potent, selective, and brain-penetrant V1a receptor antagonist, which was not suitable for full development. Nevertheless, this compound was found to improve surrogates of social behavior in adults with autism spectrum disorder in an exploratory proof-of-mechanism study. Here we describe scaffold hopping that gave rise to triazolobenzodiazepines with improved pharmacokinetic properties. The key to balancing potency and selectivity while minimizing P-gp mediated efflux was fine-tuning of hydrogen bond acceptor basicity. Ascertaining a V1a antagonist specific brain activity pattern by pharmacological magnetic resonance imaging in the rat played a seminal role in guiding optimization efforts, culminating in the discovery of balovaptan (RG7314, RO5285119) 1. In a 12-week clinical phase 2 study in adults with autism spectrum disorder balovaptan demonstrated improvements in Vineland-II Adaptive Behavior Scales, a secondary end point comprising communication, socialization, and daily living skills. Balovaptan entered phase 3 clinical development in August 2018.
- 17 January 2020
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (4) , 1511-1525
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder
We recently reported the discovery of a potent, selective, and brain-penetrant V1a receptor antagonist, which was not suitable for full development. Nevertheless, this compound was found to improve surrogates of social behavior in adults with autism spectrum disorder in an exploratory proof-of-mechanism study. Here we describe scaffold hopping that gave rise to triazolobenzodiazepines with improved pharmacokinetic properties. The key to balancing potency and selectivity while minimizing P-gp mediated efflux was fine-tuning of hydrogen bond acceptor basicity. Ascertaining a V1a antagonist specific brain activity pattern by pharmacological magnetic resonance imaging in the rat played a seminal role in guiding optimization efforts, culminating in the discovery of balovaptan (RG7314, RO5285119) 1. In a 12-week clinical phase 2 study in adults with autism spectrum disorder balovaptan demonstrated improvements in Vineland-II Adaptive Behavior Scales, a secondary end point comprising communication, socialization, and daily living skills. Balovaptan entered phase 3 clinical development in August 2018.
- Top Cited PapersOpen Access
- 25 May 2018
- Published by Springer Nature in Translational Psychiatry
- Vol. 8 (1) , 1-11
Glutamate and GABA in autism spectrum disorder—a translational magnetic resonance spectroscopy study in man and rodent models
Autism spectrum disorder (ASD) is a pervasive neurodevelopmental syndrome with a high human and economic burden. The pathophysiology of ASD is largely unclear, thus hampering development of pharmacological treatments for the core symptoms of the disorder. Abnormalities in glutamate and GABA signaling have been hypothesized to underlie ASD symptoms, and may form a therapeutic target, but it is not known whether these abnormalities are recapitulated in humans with ASD, as well as in rodent models of the disorder. We used translational proton magnetic resonance spectroscopy ([1H]MRS) to compare glutamate and GABA levels in adult humans with ASD and in a panel of six diverse rodent ASD models, encompassing genetic and environmental etiologies. [1H]MRS was performed in the striatum and the medial prefrontal cortex, of the humans, mice, and rats in order to allow for direct cross-species comparisons in specific cortical and subcortical brain regions implicated in ASD. In humans with ASD, glutamate concentration was reduced in the striatum and this was correlated with the severity of social symptoms. GABA levels were not altered in either brain region. The reduction in striatal glutamate was recapitulated in mice prenatally exposed to valproate, and in mice and rats carrying Nlgn3 mutations, but not in rodent ASD models with other etiologies. Our findings suggest that glutamate/GABA abnormalities in the corticostriatal circuitry may be a key pathological mechanism in ASD; and may be linked to alterations in the neuroligin–neurexin signaling complex.
- 25 May 2018
- Published by Springer Nature in Translational Psychiatry
- Vol. 8 (1) , 1-11
Top Cited PapersOpen AccessGlutamate and GABA in autism spectrum disorder—a translational magnetic resonance spectroscopy study in man and rodent models
Autism spectrum disorder (ASD) is a pervasive neurodevelopmental syndrome with a high human and economic burden. The pathophysiology of ASD is largely unclear, thus hampering development of pharmacological treatments for the core symptoms of the disorder. Abnormalities in glutamate and GABA signaling have been hypothesized to underlie ASD symptoms, and may form a therapeutic target, but it is not known whether these abnormalities are recapitulated in humans with ASD, as well as in rodent models of the disorder. We used translational proton magnetic resonance spectroscopy ([1H]MRS) to compare glutamate and GABA levels in adult humans with ASD and in a panel of six diverse rodent ASD models, encompassing genetic and environmental etiologies. [1H]MRS was performed in the striatum and the medial prefrontal cortex, of the humans, mice, and rats in order to allow for direct cross-species comparisons in specific cortical and subcortical brain regions implicated in ASD. In humans with ASD, glutamate concentration was reduced in the striatum and this was correlated with the severity of social symptoms. GABA levels were not altered in either brain region. The reduction in striatal glutamate was recapitulated in mice prenatally exposed to valproate, and in mice and rats carrying Nlgn3 mutations, but not in rodent ASD models with other etiologies. Our findings suggest that glutamate/GABA abnormalities in the corticostriatal circuitry may be a key pathological mechanism in ASD; and may be linked to alterations in the neuroligin–neurexin signaling complex.
- 1 April 2018
- Published by Elsevier in Biological Psychiatry
- Vol. 83 (7) , 607-617
Identification of a Corticohabenular Circuit Regulating Socially Directed Behavior
- 1 April 2018
- Published by Elsevier in Biological Psychiatry
- Vol. 83 (7) , 607-617
Identification of a Corticohabenular Circuit Regulating Socially Directed Behavior
- Open Access
- 1 August 2017
- Published by Elsevier in Cell Reports
- Vol. 20 (8) , 1867-1880
Synaptic Regulation of a Thalamocortical Circuit Controls Depression-Related Behavior
- 1 August 2017
- Published by Elsevier in Cell Reports
- Vol. 20 (8) , 1867-1880
Open AccessSynaptic Regulation of a Thalamocortical Circuit Controls Depression-Related Behavior
- Open Access
Medial prefrontal cortical NMDA receptors regulate depression-like behavior and dictate limbic thalamus innervation
Depression is a pervasive and debilitating neuropsychiatric disorder. A single, low dose of the NMDA receptor (NMDAR) antagonist ketamine elicits a long-lasting antidepressant response in patients with treatment-resistant major depressive disorder. Developing mechanistic understanding of how NMDAR antagonism alters synapse and circuit function is pivotal to developing translatable, circuit-based therapies for depression. Here using viral vectors, anatomical tracing, fMRI, and optogenetic-assisted circuit analysis, we assessed the role of the NMDAR subunit GluN2B in regulating cellular, synaptic, and circuit-level function and depression-related behavior. We demonstrate that post-developmental deletion of GluN2B from pyramidal neurons in medial prefrontal cortex enhances action potential output in a synaptic activity-dependent manner. GluN2B deletion dictates functional connectivity between mPFC and limbic thalamus but not ventral hippocampus and elicits antidepressant-like behavior. Our findings demonstrate that postsynaptic GluN2B exerts input-specific control of pyramidal neuron innervation, and identify a novel circuit for regulating depression-like behaviors in mice.
Open AccessMedial prefrontal cortical NMDA receptors regulate depression-like behavior and dictate limbic thalamus innervation
Depression is a pervasive and debilitating neuropsychiatric disorder. A single, low dose of the NMDA receptor (NMDAR) antagonist ketamine elicits a long-lasting antidepressant response in patients with treatment-resistant major depressive disorder. Developing mechanistic understanding of how NMDAR antagonism alters synapse and circuit function is pivotal to developing translatable, circuit-based therapies for depression. Here using viral vectors, anatomical tracing, fMRI, and optogenetic-assisted circuit analysis, we assessed the role of the NMDAR subunit GluN2B in regulating cellular, synaptic, and circuit-level function and depression-related behavior. We demonstrate that post-developmental deletion of GluN2B from pyramidal neurons in medial prefrontal cortex enhances action potential output in a synaptic activity-dependent manner. GluN2B deletion dictates functional connectivity between mPFC and limbic thalamus but not ventral hippocampus and elicits antidepressant-like behavior. Our findings demonstrate that postsynaptic GluN2B exerts input-specific control of pyramidal neuron innervation, and identify a novel circuit for regulating depression-like behaviors in mice.
- Open Access
- 1 March 2017
- Published by Elsevier in Neuroscience
- Vol. 344, 346-359
Altered fronto-striatal functions in the Gdi1-null mouse model of X-linked Intellectual Disability
- 1 March 2017
- Published by Elsevier in Neuroscience
- Vol. 344, 346-359
Open AccessAltered fronto-striatal functions in the Gdi1-null mouse model of X-linked Intellectual Disability
- Open Access
- 15 April 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 24523
A novel anesthesia regime enables neurofunctional studies and imaging genetics across mouse strains
Functional magnetic resonance imaging (fMRI) has revolutionized neuroscience by opening a unique window that allows neurocircuitry function and pathological alterations to be probed non-invasively across brain disorders. Here we report a novel sustainable anesthesia procedure for small animal neuroimaging that overcomes shortcomings of anesthetics commonly used in rodent fMRI. The significantly improved preservation of cerebrovascular dynamics enhances sensitivity to neural activity changes for which it serves as a proxy in fMRI readouts. Excellent cross-species/strain applicability provides coherence among preclinical findings and is expected to improve translation to clinical fMRI investigations. The novel anesthesia procedure based on the GABAergic anesthetic etomidate was extensively validated in fMRI studies conducted in a range of genetically engineered rodent models of autism and strains commonly used for transgenic manipulations. Etomidate proved effective, yielded long-term stable physiology with basal cerebral blood flow of ~0.5 ml/g/min and full recovery. Cerebrovascular responsiveness of up to 180% was maintained as demonstrated with perfusion- and BOLD-based fMRI upon hypercapnic, pharmacological and sensory stimulation. Hence, etomidate lends itself as an anesthetic-of-choice for translational neuroimaging studies across rodent models of brain disorders.
- 15 April 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 24523
Open AccessA novel anesthesia regime enables neurofunctional studies and imaging genetics across mouse strains
Functional magnetic resonance imaging (fMRI) has revolutionized neuroscience by opening a unique window that allows neurocircuitry function and pathological alterations to be probed non-invasively across brain disorders. Here we report a novel sustainable anesthesia procedure for small animal neuroimaging that overcomes shortcomings of anesthetics commonly used in rodent fMRI. The significantly improved preservation of cerebrovascular dynamics enhances sensitivity to neural activity changes for which it serves as a proxy in fMRI readouts. Excellent cross-species/strain applicability provides coherence among preclinical findings and is expected to improve translation to clinical fMRI investigations. The novel anesthesia procedure based on the GABAergic anesthetic etomidate was extensively validated in fMRI studies conducted in a range of genetically engineered rodent models of autism and strains commonly used for transgenic manipulations. Etomidate proved effective, yielded long-term stable physiology with basal cerebral blood flow of ~0.5 ml/g/min and full recovery. Cerebrovascular responsiveness of up to 180% was maintained as demonstrated with perfusion- and BOLD-based fMRI upon hypercapnic, pharmacological and sensory stimulation. Hence, etomidate lends itself as an anesthetic-of-choice for translational neuroimaging studies across rodent models of brain disorders.
- 1 September 2015
- Published by Elsevier in Psychiatry Research
- Vol. 233 (3) , 394-401
Temporal profile of brain response to alprazolam in patients with generalized anxiety disorder
- 1 September 2015
- Published by Elsevier in Psychiatry Research
- Vol. 233 (3) , 394-401
Temporal profile of brain response to alprazolam in patients with generalized anxiety disorder
- 1 May 2015
- Published by Elsevier in NeuroImage
- Vol. 112, 70-85
“Domain gauges”: A reference system for multivariate profiling of brain fMRI activation patterns induced by psychoactive drugs in rats
- 1 May 2015
- Published by Elsevier in NeuroImage
- Vol. 112, 70-85
“Domain gauges”: A reference system for multivariate profiling of brain fMRI activation patterns induced by psychoactive drugs in rats